Biolyst › AAPGASCENTAGE PHARMA GROUP INTERNATIONAL is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL on December 15, 2026. There are 16 upcoming events on record.
Across 15 concluded trials, 60% reached completion rather than being terminated or withdrawn.
Upcoming catalysts
Date Event Type Phase
December 15, 2026
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL Trial Milestone
Phase 2
December 31, 2026
Global Trial in APG2575 for Patients With CLL/SLL Trial Milestone
Phase 3
March 31, 2027
A Study of Olverembatinib in SDH-deficient GIST. Trial Milestone
Phase 3
May 15, 2027
APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST Trial Milestone
Phase 1
June 1, 2027
APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors Trial Milestone
Phase 1/Phase 2
June 30, 2027
Study of Olverembatinib (HQP1351) in Patients With CML-CP Trial Milestone
Phase 3
August 15, 2027
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. Trial Milestone
Phase 3
December 15, 2027
APG-2449 in Patients With Advanced Solid Tumors Trial Milestone
Phase 1
December 15, 2027
A Study of HQP1351 in Patients With GIST or Other Solid Tumors Trial Milestone
Phase 1
December 31, 2027
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918. Trial Milestone
Phase 1
December 31, 2027
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1) Trial Milestone
Phase 3
May 25, 2028
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia Trial Milestone
Phase 3
September 15, 2028
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML Trial Milestone
Phase 1/Phase 2
June 15, 2029
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4). Trial Milestone
Phase 3
December 15, 2029
A Study of APG-3288 in Relapsed/Refractory Blood Cancers Trial Milestone
Phase 1
December 27, 2029
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL Trial Milestone
Phase 1
Track AAPG alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open AAPG in the tracker
Recent history
Date Event Type Phase
September 29, 2026
6-K filed: Foreign issuer report Filing
—
September 17, 2026
6-K filed: Foreign issuer report Filing
—
August 20, 2026
6-K filed: Foreign issuer report Filing
—
August 13, 2026
6-K filed: Foreign issuer report Filing
—
August 5, 2026
6-K filed: Foreign issuer report Filing
—
August 3, 2026
6-K filed: Foreign issuer report Filing
—
July 27, 2026
6-K filed: Foreign issuer report Filing
—
July 20, 2026
6-K filed: Foreign issuer report Filing
—
July 13, 2026
6-K filed: Foreign issuer report Filing
—
June 30, 2026
6-K filed: Foreign issuer report Filing
—
June 30, 2026
Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment Trial Milestone
Phase 1
June 15, 2026
6-K filed: Foreign issuer report Filing
—
June 12, 2026
6-K filed: Foreign issuer report Filing
—
June 10, 2026
6-K filed: Foreign issuer report Filing
—
June 1, 2026
6-K filed: Foreign issuer report Filing
—
May 31, 2026
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL Trial Milestone
Phase 2
May 28, 2026
6-K filed: Foreign issuer report Filing
—
May 28, 2026
6-K filed: Foreign issuer report Filing
—
May 22, 2026
6-K filed: Foreign issuer report Filing
—
May 13, 2026
6-K filed: Foreign issuer report Filing
—
May 12, 2026
6-K filed: Foreign issuer report Filing
—
May 1, 2026
6-K filed: Foreign issuer report Filing
—
April 29, 2026
Results filed (20-F) Earnings
—
April 22, 2026
6-K filed: Foreign issuer report Filing
—
April 20, 2026
6-K filed: Foreign issuer report Filing
—
April 15, 2026
A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus. Trial Milestone
Phase 1/Phase 2
April 15, 2026
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors Trial Milestone
Phase 1/Phase 2
April 1, 2026
6-K filed: Foreign issuer report Filing
—
March 26, 2026
6-K filed: Foreign issuer report Filing
—
March 18, 2026
6-K filed: Foreign issuer report Filing
—
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.